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L E T T E R  T O  T H E  E D I T O R
Innate lymphoid cells type 2 in LTP- allergic patients and their 
modulation during sublingual immunotherapy
To the Editor
Lipid transfer protein allergy induces complex clinical manifesta-
tions, often severe or life- threatening in food allergy (FA).1 It is 
characterised by an immunologic tolerance breakdown to ingested 
food associated with the immunological response type 2. The innate 
lymphoid cell type 2 (ILC2) have emerged as key in FA, mainly in 
animal models.2 ILC2 share morphological characteristics with lym-
phocytes, with no expression of allergen recognition receptors, with 
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TA B L E  1  Clinical characteristics and allergological work- up results















LTP- AP1 34 F Grass/olive Yes Persistent- mild No Anaph 5 >3 8 6.96
LTP- AP2 44 M Grass Yes Persistent- 
moderate
No U 17 >3 8 20.6
LTP- AP3 39 F – No – No U/Ang 15 >3 9 10.9
LTP- AP4 32 F Grass/olive Yes Intermittent- 
mild
No U 12 >3 7 34.4
LTP- AP5 48 M Olive Yes Persistent- 
moderate
No Anaph 15 >3 8 3.58
LTP- AP6 27 F Grass/olive Yes Persistent- mild No Anaph 2 >3 10 5.26
LTP- AP7 31 F – No – No U 8 >3 10 7.85
LTP- AP8 28 F – No – No U/Ang 5 1 8 1.05
LTP- AP9 37 M – No – No Ang 30 1 7 8.16
LTP- AP10 49 F Grass Yes Persistent- mild No Anaph 10 1 13 13.2
TC1 35 F – No – No T – – – <0.35
TC2 48 M – No – No T – – – <0.35
TC3 46 M HDM Yes Persistent- 
moderate
No T – – – <0.35
TC4 48 M Olive Yes Persistent- mild No T – – – <0.35
TC5 22 F – No – No T – – – <0.35
TC6 39 F HDM Yes Persistent- 
moderate
No T – – – <0.35
TC7 26 F Olive Yes Persistent- mild No T – – – <0.35
TC8 46 M Olive Yes Persistent- 
moderate
No T – – – <0.35
TC9 48 M HDM Yes Persistent- mild No T – – – <0.35
TC10 39 M HDM Yes Persistent- 
moderate
No T – – – <0.35
Note: OPS, Onset of Peach Symptoms is the time (min) that has passed from the first reaction with peach to the patient evaluation in the consultation. 
Marked in bold letters, patients who were treated with SLIT- Prup3.
Abbreviations: Anaph, anaphylaxis; HDM, House Dust Mite; LTP- AP, Lipid transfer protein- allergic patients; N, number; SPT, Skin prick test and sIgE 
to Pru p 3; T, tolerant; TC, tolerant control; U/Ang, urticaria and/or angioedema.
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expression of transcription factor GATA- 3, and receptors for IL- 25, 
IL- 33 and thymic stromal lymphopoietin (TSLP). ILC2 are activated 
by these cytokines, originating their expansion and production of 
Th2- cytokines.3 Furthermore, a distinct subset of ILC2 with regu-
latory function with IL- 10 production, which can be activated by 
different immunological pathways and by retinoic acid, has been 
F I G U R E  1  ILC2 analysis. (A) ILC2 percentages in LTP- allergic patients (LTP- AP, N = 10) and tolerant controls (TC, N = 10); (B) Correlation of the 
IL- 4+ and IL- 13+ILC2 percentages vs clinical parameters. (C) ILC2 percentages in LTP- AP with Urticaria and/or Angioedema (without colour, U/Ang, 
N = 6) and Anaphylaxis (with colour, Anaph, N = 4); (D) Changes in the total ILC2 and their phenotypes during SLIT- Prup3 in treated LTP- AP (N = 7) 
(T0, T1, T6 and T12), in non- treated LTP- AP, and TC at only one point. (E) IL- 4, IL- 13 and IL- 10 percentages in ILC2 from treated LTP- AP (at T12), 
from non- treated LTP- AP, and TC at only one point. Bars plus symbols represent the mean and SEM. The symbols indicate individual data points for 
the different groups of study. The significant differences are represented as p- values <0.05
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characterised.4 However, the innate immune cell involvement in the 
allergic disease remains to be elucidated, specifically ILC2 implica-
tion in loss of tolerance to food allergens in humans.
There is a great interest in exploring how ILC2 can be affected 
by allergen- specific immunotherapy (AIT), postulating them as a 
biomarker predictor of responses.5 We demonstrated the safety 
and effectiveness of sublingual immunotherapy (SLIT) using Pru p 
3- enriched extracts (SLIT- Prup3),6 showing allergen- specific Th2- 
cell modulation, involving dendritic cell (DC) activity and inducing 
a regulatory pattern.7 However, the effect of SLIT- Prup3 on ILC2 is 
yet to be determined.
We report for the first time ILC2 implication in LTP allergy and 
SLIT- Prup3 ability to modulate effector Th2 cells and ILC2 in LTP- 
allergic patients (LTP- AP). This study included LTP- AP and toler-
ant controls without FA (TC) (Table 1). From these, seven LTP- AP 
were chosen for presenting more allergic episodes after peach in-
take and systemic symptoms (Table 1), treated with (SLIT- Prup3- 
LTP- AP) for 1 year and evaluated at different time points (T0, T1, 
T6, T12 months). From all subjects, peripheral blood mononuclear 
cells (PBMCs) were obtained, stimulated and phenotypically char-
acterised by flow cytometry as ILC2 and T cells (Figures S1- S2) and 
the possible relationship of ILC2 with T cells and clinical parameters 
analysed. Further methods details are included in the OS.
Our results suggest that ILC2, IL- 4+ and IL- 13+ILC2 (Figure 1A) 
as well as IL- 4+ and IL- 13+ Th2 cell percentages (Figure S3A) were 
significantly higher in LTP- AP than in TC.8 This could indicate that 
the type 2 immune response in FA is mediated by an apparent action 
of Th2 cells and ILC2. Moreover, there was a positive correlation 
between both cell types, significant for IL- 13+ILC2 vs IL- 13+Th2 cells 
(Figure S3B).
Furthermore, IL- 4+ and IL- 13+ILC2 frequencies in LTP- AP had 
a strong positive correlation with skin prick test and Pru p 3- sIgE 
levels (Figure 1B). Although limited by the sample size, LTP- AP with 
anaphylaxis symptoms had higher IL- 4+ and IL- 13+ILC2 levels com-
pared with LTP- AP with mild symptoms (urticaria and angioedema) 
(Figure 1C). These observations, together with the link between ILC2 
and the IgE- mediated adaptive response, represent an important ad-
vance in the ILC2 role in FA, suggesting them as a potential thera-
peutic target for FA in clinical practise. Moreover, the different ILC2 
phenotype frequencies and their correlations with aeroallergen- sIgE 
in LTP- AP and TC with or without rhinitis demonstrated that the dif-
ferences found between LTP- AP and TC are mediated by Pru p 3 and 
not by the respiratory symptoms (data not shown).
We characterised the ILC2 profile during SLIT- Prup3 in PBMCs 
from LTP- AP treated for 1 year (Table S2 and Figure S4A). Results 
showed a significant decrease in total ILC2 during treatment and a re-
duction in IL- 4+ and IL- 13+ILC2 frequency at T12; being significantly 
lower in SLIT- Prup3- treated LTP- AP compared with non- treated 
LTP- AP, and tending to TC levels (Figure 1D). Moreover, T cell modu-
lation by SLIT- Prup3 showed: i) a significant increase in IFNγ+Th1 and 
Treg cells and a significant decrease in IL- 4+Th2 cells at T12 (Figure 
S3C)7; and ii) a positive correlation after 1 year of treatment between 
the Th2 cells and ILC2, being significant for IL- 13+ILC2 vs IL- 13+Th2 
cells (Figure S3D). Furthermore, ILC2 were not capable of producing 
IFNγ, but they did produce IL- 10 only in treated LTP- AP (Figure 1D). 
Indeed, we considered that IL- 10+ILC2 was an independent pheno-
type without IL- 4 production by ILC2 (Figure S1); and after 1 year of 
treatment the IL- 10 frequency was more elevated than IL- 4+ and IL- 
13+ frequencies in the ILC2 (Figure 1E). These results suggested that 
SLIT- Prup3 could induce a new immunomodulatory function of acti-
vated IL- 10+ILC2. Although not directly studied in this work, immu-
nological pathways, implicating the retinoic acid or IFNy production, 
could be associated with downregulated pro- inflammatory genes 
distinct from those that induce IL- 4+ or IL- 13+ILC2.4,9 Moreover, we 
observed a significant negative correlation between IL- 13+ILC2; and 
IL- 4+ILC2 with the regulatory pattern of ILC2 in LTP- AP treated for 
T12 (Figure S5A). These results suggest that SLIT could modulate the 
regulatory ILC2 phenotype. Furthermore, our results showed the 
significant positive correlation of Treg cells vs IL- 10+ILC2 stimulated 
by SLIT- Prup3 in LTP- AP at T12 (Figure S5B). The correlation analysis 
between the regulatory pattern (Treg cells and IL- 10+ILC2) and clin-
ical characteristics after T12 showed positive correlations (Figures 
S4B- S5C), significant for Treg cells vs Pru p 3- sIgG4. Although most 
of these correlations were not significant, probably because of the 
sample size, suggested the possible implication of regulatory cells in 
the tolerance response induced by AIT.
Our results report the first evidence of the presence of ILC2 
in FA patients and their modulation by specific immunotherapy. 
Overall, we have identified and characterised peripheral ILC2 in 
LTP- AP, with frequencies closely related to clinical parameters (in 
vivo) together with Pru p 3- sIgE levels and Th2 cells. Furthermore, 
SLIT- Prup3 could change their type 2 response phenotype frequen-
cies in peripheral blood towards a regulatory phenotype, associated 
with regulatory pattern of the adaptive T cells, suggesting their con-
tribution to clinical and immunological tolerance. We are aware of 
the need of more studies, if the changes in the ILC2 frequency are 
maintained in the time; and on a larger population for AIT with Pru 
p 3 and specific cytokines to stimulate the ILC2 and analysing the 
IL10+ILC2 functionality in the immunomodulation. Even so, these 
findings offer new information on ILC2 participation in loss of toler-
ance in FA, postulating them as therapeutic targets and biomarkers 
to predict food- immunotherapy responses.
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